Research programme: phosphodiesterase IV inhibitors - Taiho
Alternative Names: PDE4 inhibitors research programme - Taiho; Phosphodiesterase IV inhibitors research programme - Taiho; Research programme: PDE4 inhibitors - Taiho; TAS-203Latest Information Update: 30 Mar 2010
Price :
$50 *
At a glance
- Originator Taiho Pharmaceutical
- Class Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Chronic bronchitis; Cystic fibrosis
Most Recent Events
- 22 Jun 2004 Preclinical trials in Asthma in Japan (PO)
- 22 Jun 2004 Preclinical trials in Chronic bronchitis in Japan (PO)
- 22 Jun 2004 Preclinical trials in Cystic fibrosis in Japan (PO)